Compare CNXN & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | MANE |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1997 | N/A |
| Metric | CNXN | MANE |
|---|---|---|
| Price | $63.78 | $73.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $78.33 |
| AVG Volume (30 Days) | 49.4K | ★ 449.2K |
| Earning Date | 04-29-2026 | 03-30-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $19.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.97 | $36.26 |
| 52 Week High | $71.17 | $80.90 |
| Indicator | CNXN | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 61.11 |
| Support Level | $56.14 | $54.23 |
| Resistance Level | $65.39 | N/A |
| Average True Range (ATR) | 1.62 | 6.13 |
| MACD | 0.41 | 0.69 |
| Stochastic Oscillator | 78.92 | 72.08 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.